Dr Hubert Birner was appointed Member of the Supervisory Board in June 2005, when Evotec had reacquired full ownership interest in Evotec Neurosciences from TVM Capital as the lead and other venture capital investors. He joined TVM Capital in 2000 and is General Partner for life sciences in the firm’s Munich office. Prior to that, he was Head of Business Development Europe and Director of Marketing Germany at Zeneca. Dr Birner joined Zeneca from McKinsey & Company's European Health Care and Pharmaceutical practice. As a Management Consultant, he gained extensive experience in R&D management, marketing & sales as well as joint venture structuring and business development. Dr Birner was also an Assistant Professor for biochemistry at the Ludwig-Maximilians-University in Munich. In this capacity, he directed various research projects for large pharmaceutical companies.
He currently serves as Chairman of the Board of Argos Therapeutics Inc. and is a Member of the Board of Directors of BioXell SA, Spepharm Holding BV, Proteon Therapeutics, Inc, Transmolecular Inc. and Nitec Pharma SA. Over many years, he was the Chairman/Vice Chairman of Direvo Biotech AG and Jerini AG which were acquired in 2008 by Bayer HealthCare AG and Shire Ltd. Dr Birner also represents the interests of TVM Capital with Ardana Bioscience plc.
Dr Birner holds an MBA from Harvard Business School and a "summa cum laude" doctoral degree in biochemistry from Ludwig-Maximilians-University Munich. His doctoral thesis was honoured with the Hoffmann-La Roche prize for outstanding basic research in metabolic diseases.